This multicenter phase 3 #ClinicalTrial demonstrated that #Socazolimab plus #Carboplatin and #Etoposide significantly improves survival in extensive-stage small cell lung cancer, offering a potent first-line immunochemotherapeutic option.

#OpenAccess: doi.org/10.1038/s413...

A phase 3 #ClinicalTrial evaluating the efficacy of #socazolimab on #ESSCLC revealed that combining socazolimab with #carboplatin-#etoposide prolonged the overall survival without further side-effects. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...